Although the methylene blue drug label does not specifically mention genetic testing, precaution prior to initiating treatment with methylene blue is highlighted for G6PD deficient individuals, a condition caused by variants in the G6PD gene which can be determined by enzymatic or genetic tests.
Excerpt from the methylene blue drug label:
Methylene blue should be avoided in patients with G6PD deficiency due to the risk of paradoxical methemoglobinemia and hemolysis.
For the complete drug label text with sections containing pharmacogenetic information highlighted, see the methylene blue drug label.
*Disclaimer: The contents of this page are the sole responsibility of PharmGKB.